Cargando…

Carboxyl‐Terminal Modulator Protein Ameliorates Pathological Cardiac Hypertrophy by Suppressing the Protein Kinase B Signaling Pathway

BACKGROUND: Carboxyl‐terminal modulator protein (CTMP) has been implicated in cancer, brain injury, and obesity. However, the role of CTMP in pathological cardiac hypertrophy has not been identified. METHODS AND RESULTS: In this study, decreased expression of CTMP was observed in both human failing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiaoxiong, Yang, Qin, Zhu, Li‐Hua, Liu, Jia, Deng, Ke‐Qiong, Zhu, Xue‐Yong, Liu, Ye, Gong, Jun, Zhang, Peng, Li, Shuyan, Xia, Hao, She, Zhi‐Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064906/ https://www.ncbi.nlm.nih.gov/pubmed/29945911 http://dx.doi.org/10.1161/JAHA.118.008654

Ejemplares similares

Novel Role for Pleckstrin Homology‐Like Domain Family A, Member 3 in the Regulation of Pathological Cardiac Hypertrophy
por: Liu, Jia, et al.
Publicado: (2019)

Heat shock protein 70-mediated sensitization of cells to apoptosis by Carboxyl-Terminal Modulator Protein
por: Piao, Longzhen, et al.
Publicado: (2009)

Carboxyl-terminal modulator protein facilitates tumor metastasis in triple-negative breast cancer
por: Lin, Cheng-Han, et al.
Publicado: (2022)

Ciliopathy-Associated Protein Kinase ICK Requires Its Non-Catalytic Carboxyl-Terminal Domain for Regulation of Ciliogenesis
por: Oh, Yoon Seon, et al.
Publicado: (2019)

Sophoricoside ameliorates cardiac hypertrophy by activating AMPK/mTORC1-mediated autophagy
por: Gao, Maomao, et al.
Publicado: (2020)

Characterization of Two Monoclonal Antibodies That Recognize Linker Region and Carboxyl Terminal Domain of Coronavirus Nucleocapsid Protein
por: Zhang, Xin, et al.
Publicado: (2016)

The Carboxyl Terminal Regions of P0 Protein Are Required for Systemic Infections of Poleroviruses
por: Zhang, Xin, et al.
Publicado: (2022)

Responsive Protein Hydrogels Assembled from Spider Silk Carboxyl-Terminal Domain and Resilin Copolymers
por: Luo, Fang, et al.
Publicado: (2018)

Oligomerization of the carboxyl terminal domain of the human coronavirus 229E nucleocapsid protein
por: Lo, Yu-Sheng, et al.
Publicado: (2013)

Cathepsin‐L Ameliorates Cardiac Hypertrophy Through Activation of the Autophagy–Lysosomal Dependent Protein Processing Pathways
por: Sun, Mei, et al.
Publicado: (2013)

Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy
por: Deng, Ke-Qiong, et al.
Publicado: (2016)

MicroRNA-137 Targets Carboxyl-terminal Binding Protein 1 in Melanoma Cell Lines
por: Deng, Yu, et al.
Publicado: (2011)

Carvacrol Ameliorates Pathological Cardiac Hypertrophy in Both In-vivo and In-vitro Models
por: Jamhiri, Mohabbat, et al.
Publicado: (2019)

Inhibition of Receptor Interacting Protein Kinases Attenuates Cardiomyocyte Hypertrophy Induced by Palmitic Acid
por: Zhao, Mingyue, et al.
Publicado: (2016)

Carboxylic Terminated Thermo-Responsive Copolymer Hydrogel and Improvement in Peptide Release Profile
por: Rao, Zi-Kun, et al.
Publicado: (2018)

Mitochondria in Pathological Cardiac Hypertrophy Research and Therapy
por: Yang, Dan, et al.
Publicado: (2022)

Smad Nuclear Interacting Protein 1 Acts as a Protective Regulator of Pressure Overload‐Induced Pathological Cardiac Hypertrophy
por: Lu, Yu‐yan, et al.
Publicado: (2016)

Suppression of calcium-sensing receptor ameliorates cardiac hypertrophy through inhibition of autophagy
por: LIU, LEI, et al.
Publicado: (2016)

Muscle hypertrophy in hypoxia with inflammation is controlled by bromodomain and extra-terminal domain proteins
por: Chabert, Clovis, et al.
Publicado: (2017)

The carboxyl-terminal sequence of PUMA binds to both anti-apoptotic proteins and membranes
por: Pemberton, James M, et al.
Publicado: (2023)

AMP-Activated Protein Kinase Signalling in Cancer and Cardiac Hypertrophy
por: Lipovka, Yulia, et al.
Publicado: (2015)

CDC-like kinase 4 deficiency contributes to pathological cardiac hypertrophy by modulating NEXN phosphorylation
por: Huang, Jian, et al.
Publicado: (2022)

Treatment of myocardial interstitial fibrosis in pathological myocardial hypertrophy
por: Zhu, Fuyu, et al.
Publicado: (2022)

Vaspin Ameliorates Cardiac Remodeling by Suppressing Phosphoinositide 3-Kinase/Protein Kinase B Pathway to Improve Oxidative Stress in Heart Failure Rats
por: Ji, Mingyue, et al.
Publicado: (2022)

Author Correction: Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy
por: Deng, Ke-Qiong, et al.
Publicado: (2023)

Changes and significance of serum ubiquitin carboxyl-terminal hydrolase L1 and glial fibrillary acidic protein in patients with glioma
por: Zhu, Qing-Hua, et al.
Publicado: (2023)

Mitogen‐Activated Protein Kinase and Intracellular Polyamine Signaling Is Involved in TRPV1 Activation–Induced Cardiac Hypertrophy
por: Chen, Mai, et al.
Publicado: (2016)

Polydatin Ameliorates Osteoporosis via Suppression of the Mitogen-Activated Protein Kinase Signaling Pathway
por: Lin, Ze, et al.
Publicado: (2021)

Actin-Binding Proteins in Cardiac Hypertrophy
por: Pan, Congbin, et al.
Publicado: (2022)

G protein-coupled receptor kinase 2 promotes cardiac hypertrophy
por: Schlegel, Philipp, et al.
Publicado: (2017)

Cordycepin ameliorates cardiac hypertrophy via activating the AMPKα pathway
por: Wang, Hui‐Bo, et al.
Publicado: (2019)

Ca2+/calmodulin‐dependent protein kinase II and protein kinase G oxidation contributes to impaired sarcomeric proteins in hypertrophy model
por: Gömöri, Kamilla, et al.
Publicado: (2022)

Resveratrol Ameliorates Cardiac Hypertrophy by Down‐regulation of miR‐155 Through Activation of Breast Cancer Type 1 Susceptibility Protein
por: Fan, Yuhua, et al.
Publicado: (2016)

Compartmentalization Role of A-Kinase Anchoring Proteins (AKAPs) in Mediating Protein Kinase A (PKA) Signaling and Cardiomyocyte Hypertrophy
por: Rababa’h, Abeer, et al.
Publicado: (2014)

Ouabain prevents pathological cardiac hypertrophy and heart failure through activation of phosphoinositide 3-kinase α in mouse
por: Wu, Jian, et al.
Publicado: (2015)

Epigenetic Reader Bromodomain Containing Protein 2 Facilitates Pathological Cardiac Hypertrophy via Regulating the Expression of Citrate Cycle Genes
por: Lin, Zhirong, et al.
Publicado: (2022)

Mutational Analysis and Allosteric Effects in the HIV-1 Capsid Protein Carboxyl-Terminal Dimerization Domain
por: Yu, Xiang, et al.
Publicado: (2009)

Novel genomic targets of valosin-containing protein in protecting pathological cardiac hypertrophy
por: Zhou, Ning, et al.
Publicado: (2020)

O‐GlcNAc Transferase Promotes Compensated Cardiac Function and Protein Kinase A O‐GlcNAcylation During Early and Established Pathological Hypertrophy From Pressure Overload
por: Zhu, Wei‐Zhong, et al.
Publicado: (2019)

Translocase of Inner Membrane 50 Functions as a Novel Protective Regulator of Pathological Cardiac Hypertrophy
por: Tang, Kai, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3h9rh2jnoameqm73p2do0riuhs